ZIPPITY DOOS LEAVE-IN DETANGLER FOR CHILDREN- rosemary oil spray United States - English - NLM (National Library of Medicine)

zippity doos leave-in detangler for children- rosemary oil spray

laurus enterprises, llc - rosmarinus officinalis (rosemary) leaf oil. - topical hair detangler.

ZIPPITY DOOS FOR CHILDREN- rosemary oil shampoo United States - English - NLM (National Library of Medicine)

zippity doos for children- rosemary oil shampoo

laurus enterprises, llc - rosmarinus officinalis (rosemary) leaf oil. - topical shampoo.

ZIPPITY DOOS CONDITIONER FOR CHILDREN- rosemary oil liquid United States - English - NLM (National Library of Medicine)

zippity doos conditioner for children- rosemary oil liquid

laurus enterprises, llc - rosmarinus officinalis (rosemary) leaf oil. - topical conditioner.

ZIPPITY DOOS STYLING FOR CHILDREN- rosemary gel United States - English - NLM (National Library of Medicine)

zippity doos styling for children- rosemary gel

laurus enterprises, llc - rosmarinus officinalis (rosemary) leaf extract. - topical hair gel.

ZIPPITY DOOS SHIELD- rosemary liquid United States - English - NLM (National Library of Medicine)

zippity doos shield- rosemary liquid

laurus enterprises, llc - rosmarinus officinalis (rosemary) leaf oil (0.1%), cymbopogon nardus (citronella) oil (0.1%). - topical or surface spray to protect against lice.

LOPINAVIR AND RITONAVIR tablet, film coated United States - English - NLM (National Library of Medicine)

lopinavir and ritonavir tablet, film coated

laurus labs limited - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions (7.1) and clinical pharmacology (12.3)] .          

ABACAVIR AND LAMIVUDINE tablet, film coated United States - English - NLM (National Library of Medicine)

abacavir and lamivudine tablet, film coated

laurus labs limited - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta

LEVETIRACETAM tablet United States - English - NLM (National Library of Medicine)

levetiracetam tablet

laurus generics inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam tablets are indicated for the treatment of partial- onset seizures in patients 1 month of age and older. levetiracetam tablets are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam tablets are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. levetiracetam tablet is contraindicated in patients with a hypersensitivity to levetiracetam . reactions have included anaphylaxis and angioedema [ see warnings and precautions (5.4) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who are taking levetiracetam during pregnancy to enroll in the

GABAPENTIN capsule United States - English - NLM (National Library of Medicine)

gabapentin capsule

laurus labs limited - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin capsules are indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin capsules are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as gabapentin, during pregnancy. encourage women who are taking gabapentin during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary there are no adequate data on the developmental risks associated with the use of gabapentin in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic (increas